WO2003040365A3 - Pna-konjugat oder pna-konjugat-gemisch zur therapie von mit hpv in zusammenhang stehenden erkrankungen - Google Patents
Pna-konjugat oder pna-konjugat-gemisch zur therapie von mit hpv in zusammenhang stehenden erkrankungen Download PDFInfo
- Publication number
- WO2003040365A3 WO2003040365A3 PCT/DE2002/004153 DE0204153W WO03040365A3 WO 2003040365 A3 WO2003040365 A3 WO 2003040365A3 DE 0204153 W DE0204153 W DE 0204153W WO 03040365 A3 WO03040365 A3 WO 03040365A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pna
- conjugate
- human papillomavirus
- treating diseases
- diseases related
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10154831.1 | 2001-11-08 | ||
DE10154831A DE10154831A1 (de) | 2001-11-08 | 2001-11-08 | PNA-Konjugat oder PNA-Konjugat-Gemisch zur Therapie von mit HPV in Zusammenhang stehenden Erkrankungen |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003040365A2 WO2003040365A2 (de) | 2003-05-15 |
WO2003040365A3 true WO2003040365A3 (de) | 2003-12-11 |
Family
ID=7705014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2002/004153 WO2003040365A2 (de) | 2001-11-08 | 2002-11-08 | Pna-konjugat oder pna-konjugat-gemisch zur therapie von mit hpv in zusammenhang stehenden erkrankungen |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE10154831A1 (de) |
WO (1) | WO2003040365A2 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10133307A1 (de) * | 2001-07-12 | 2003-02-06 | Deutsches Krebsforsch | PNA-Konjugat zur Therapie von mit HIV in Zusammenhang stehenden Erkrankungen |
CN104404076B (zh) * | 2014-11-04 | 2017-10-03 | 珠海雅马生物工程有限公司 | 利用锌指核酸酶敲除人乳头瘤病毒e6e7基因的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020095A1 (en) * | 1992-03-31 | 1993-10-14 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of papillomavirus |
WO1999013071A1 (en) * | 1997-09-05 | 1999-03-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human papilloma virus inhibition by anti-sense oligonucleotides |
DE19933492A1 (de) * | 1999-07-16 | 2001-01-18 | Deutsches Krebsforsch | Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028942A1 (en) * | 1994-04-26 | 1995-11-02 | Genta Incorporated | Antisense oligomers for inhibiting human papillomaviruses |
US6312956B1 (en) * | 1999-10-01 | 2001-11-06 | Vanderbilt University | Nuclear targeted peptide nucleic acid oligomer |
-
2001
- 2001-11-08 DE DE10154831A patent/DE10154831A1/de not_active Withdrawn
-
2002
- 2002-11-08 WO PCT/DE2002/004153 patent/WO2003040365A2/de not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020095A1 (en) * | 1992-03-31 | 1993-10-14 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of papillomavirus |
WO1999013071A1 (en) * | 1997-09-05 | 1999-03-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human papilloma virus inhibition by anti-sense oligonucleotides |
DE19933492A1 (de) * | 1999-07-16 | 2001-01-18 | Deutsches Krebsforsch | Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen |
WO2001005432A2 (de) * | 1999-07-16 | 2001-01-25 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Konjugat zur vermittlung eines zell-, kompartiment- oder membranspezifischen transports von wirksubstanzen |
Non-Patent Citations (3)
Title |
---|
DEROSSI D ET AL: "Trojan peptides: the penetratin system for intracellular delivery", TRENDS IN CELL BIOLOGY, ELSEVIER SCIENCE LTD, XX, vol. 8, no. 2, February 1998 (1998-02-01), pages 84 - 87, XP002122131, ISSN: 0962-8924 * |
MADRIGAL MARILU ET AL: "In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma.", GYNECOLOGIC ONCOLOGY, vol. 64, no. 1, 1997, pages 18 - 25, XP002255064, ISSN: 0090-8258 * |
PIPKORN R ET AL: "Synthesis of functional peptides for therapy of HPV 18 positive HeLa cervix cancer cells.", BIOPOLYMERS, vol. 71, no. 3, 2003, & 18TH AMERICAN PEPTIDE SYMPOSIUM ON PEPTIDE REVOLUTION: GENOMICS, PROTEOMICS AND THERAPEUTICS; BOSTON, MA, USA; JULY 19-23, 2003, pages 409, XP002255065, ISSN: 0006-3525 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003040365A2 (de) | 2003-05-15 |
DE10154831A1 (de) | 2003-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Steger et al. | Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein | |
CA2795906C (en) | Hpv particles and uses thereof | |
O'Brien et al. | Evasion of host immunity directed by papillomavirus-encoded proteins | |
WO2000014244A3 (en) | Treatment of cervical cancer | |
WO2007121894A3 (en) | Hpv-18-based papillomavirus vaccine | |
WO2007121895A3 (en) | Hpv-16-based papillomavirus vaccine | |
AP1872A (en) | Virus-like particles of human papillomavirus. | |
HK1085378A1 (en) | Use of hpv16 and hpv18 as vaccine against one or more of oncogenic hpv type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 | |
Biliris et al. | Human papillomavirus infection of non-melanoma skin cancers in immunocompetent hosts | |
HK1090956A1 (en) | Detection of human papillomavirus | |
HUP0303942A2 (hu) | Új vakcinakészítmények | |
CA2424700A1 (en) | Genetic immunisation against cervical carcinoma | |
WO2003040365A3 (de) | Pna-konjugat oder pna-konjugat-gemisch zur therapie von mit hpv in zusammenhang stehenden erkrankungen | |
EP1149917A3 (de) | Hepatitis B Vektoren für Gentherapie | |
Fakhraei et al. | Human papillomaviruses and cancer | |
Longuet et al. | A novel genital human papillomavirus (HPV), HPV type 74, found in immunosuppressed patients | |
WO2004105681A3 (en) | Cd4+ human papillomavirus (hpv) epitopes | |
Favre et al. | Human papillomavirus (HPV) type 50, a type associated with epidermodysplasia verruciformis (EV) and only weakly related to other EV-specific HPVs | |
WO2002004595A3 (en) | Production of chimeric human papillomavirus | |
Krige et al. | Sequence variation in the Early genes E1^ E4, E6 and E7 of Human Papilloma Virus type 6 | |
SI1572233T1 (sl) | Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68 | |
Di Paolo et al. | Multistage carcinogenesis utilizing human genital cells and human papillomaviruses | |
WO2001003717A3 (en) | Methods of inducing cell death | |
Albert et al. | Demonstration of URR‐duplication variants of human papillomavirus type 6 in paraffin‐embedded tissue sections of one condyloma acuminatum and one buschke‐loewenstein tumour | |
Murahwa et al. | Complete genome sequences of four novel human Gammapapillomavirus types, HPV-219, HPV-220, HPV-221, and HPV-222, isolated from penile skin swabs from South African men. Genome Announc 6: e00584-18 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WA | Withdrawal of international application | ||
NENP | Non-entry into the national phase |
Ref country code: JP |